Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-1045 |
| Synonyms | |
| Therapy Description |
MK-1045 is a humanized bispecific antibody targeting CD19 and CD3, which may lead to increased anti-tumor immune response (Blood (2025) 146 (Supplement 1): 3740). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-1045 | MK 1045|MK1045|CN201|CN-201|CN 201 | CD19 Antibody 23 CD3 Antibody 125 | MK-1045 is a humanized bispecific antibody targeting CD19 and CD3, which may lead to increased anti-tumor immune response (Blood (2025) 146 (Supplement 1): 3740). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07519772 | Phase Ib/II | MK-1045 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Recruiting | ISR | 0 |
| NCT07570173 | Phase II | MK-1045 Blinatumomab | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | Recruiting | ISR | 0 |